SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Nielsen Johan L.) srt2:(2005-2009)"

Sökning: WFRF:(Nielsen Johan L.) > (2005-2009)

  • Resultat 1-3 av 3
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Druker, Brian J., et al. (författare)
  • Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
  • 2006
  • Ingår i: New England Journal of Medicine. - 0028-4793 .- 1533-4406. ; 355:23, s. 2408-2417
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic phase. For 5 years, we followed patients with CML who received imatinib as initial therapy. METHODS: We randomly assigned 553 patients to receive imatinib and 553 to receive interferon alfa plus cytarabine and then evaluated them for overall and event-free survival; progression to accelerated-phase CML or blast crisis; hematologic, cytogenetic, and molecular responses; and adverse events. RESULTS: The median follow-up was 60 months. Kaplan-Meier estimates of cumulative best rates of complete cytogenetic response among patients receiving imatinib were 69% by 12 months and 87% by 60 months. An estimated 7% of patients progressed to accelerated-phase CML or blast crisis, and the estimated overall survival of patients who received imatinib as initial therapy was 89% at 60 months. Patients who had a complete cytogenetic response or in whom levels of BCR-ABL transcripts had fallen by at least 3 log had a significantly lower risk of disease progression than did patients without a complete cytogenetic response (P<0.001). Grade 3 or 4 adverse events diminished over time, and there was no clinically significant change in the profile of adverse events. CONCLUSIONS: After 5 years of follow-up, continuous treatment of chronic-phase CML with imatinib as initial therapy was found to induce durable responses in a high proportion of patients. (ClinicalTrials.gov number, NCT00006343 [ClinicalTrials.gov].)
  •  
2.
  •  
3.
  • Simonsson, Bengt, et al. (författare)
  • Intensive treatment and stem cell transplantation in chronic myelogenous leukemia : long-term follow-up
  • 2005
  • Ingår i: Acta Haematologica. - : S. Karger AG. - 0001-5792 .- 1421-9662. ; 113:3, s. 155-162
  • Tidskriftsartikel (refereegranskat)abstract
    • In the present study we combined interferon (IFN) and hydroxyurea (HU) treatment, intensive chemotherapy and autologous stem cell transplantation (SCT) in newly diagnosed chronic myelogenous leukemia patients aged below 56 years, not eligible for allogeneic SCT. Patients who had an HLA-identical sibling donor and no contraindication went for an allogeneic SCT (related donor, RD). After diagnosis, patients not allotransplanted received HU and IFN to keep WBC and platelet counts low. After 6 months patients with Ph-positive cells still present in the bone marrow received 1–3 courses of intensive chemotherapy. Those who became Ph-negative after IFN + HU or after 1–3 chemotherapy courses underwent autologous SCT. Some patients with poor cytogenetic response were allotransplanted with an unrelated donor (URD). IFN + HU reduced the percentage of Ph-positive metaphases in 56% of patients, and 1 patient became Ph-negative. After one or two intensive cytotherapies 86 and 88% had a Ph reduction, and 34 and 40% became Ph-negative, respectively. In patients receiving a third intensive chemotherapy 92% achieved a Ph reduction and 8% became Ph-negative. The median survival after auto-SCT (n = 46) was 7.5 years. The chance of remaining Ph-negative for up to 10 years after autologous SCT was around 20%. The overall survival for allo-SCT RD (n = 91) and URD (n = 28) was almost the same, i.e. ≈60% at 10 years. The median survival for all 251 patients registered was 8 years (historical controls 3.5 years). The role of the treatment schedule presented in the imatinib era is discussed.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-3 av 3
Typ av publikation
tidskriftsartikel (3)
Typ av innehåll
refereegranskat (3)
Författare/redaktör
Simonsson, Bengt (2)
Overvad, Kim (1)
Turesson, Ingemar (1)
Lissner, Lauren, 195 ... (1)
Ljungman, Per (1)
Stone, Richard M. (1)
visa fler...
Björkholm, Magnus (1)
Bengtsson, Calle, 19 ... (1)
Jarvelin, Marjo-Riit ... (1)
Paul, Christer (1)
Fischer, Thomas (1)
Wahlin, Anders (1)
Linder, Olle (1)
Rasmussen, Finn (1)
Byberg, Liisa (1)
Andersen, Lise Geisl ... (1)
Angquist, Lars (1)
Gamborg, Michael (1)
Canoy, Dexter (1)
Eriksson, Johan G. (1)
Eriksson, Marit (1)
Nilsen, Tom I. (1)
Osler, Merete (1)
Salonen, Minna K. (1)
Schack-Nielsen, Lene (1)
Tammelin, Tuija H. (1)
Tuomainen, Tomi-Pekk ... (1)
Sorensen, Thorkild I ... (1)
Baker, Jennifer L. (1)
Nilsson, Jonas (1)
Carneskog, Jan (1)
Öberg, Gunnar (1)
Olsson-Strömberg, Ul ... (1)
Baccarani, Michele (1)
Saglio, Giuseppe (1)
Cervantes, Francisco (1)
Gratwohl, Alois (1)
Guilhot, François (1)
Hochhaus, Andreas (1)
Hughes, Timothy (1)
Kantarjian, Hagop (1)
Silver, Richard T. (1)
Larson, Richard A. (1)
Radich, Jerald P. (1)
Rousselot, Philippe (1)
Goldman, John M. (1)
Karlsson, Karin (1)
Gahrton, Gösta (1)
Olsson, Karin (1)
Löfvenberg, Eva (1)
visa färre...
Lärosäte
Uppsala universitet (3)
Karolinska Institutet (2)
Göteborgs universitet (1)
Umeå universitet (1)
Linköpings universitet (1)
Lunds universitet (1)
Språk
Engelska (3)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (2)
Naturvetenskap (1)
Samhällsvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy